Adicet Bio says prula-cel Phase 1 lupus study shows 54% DORIS remission at 12 months
Bitget2026/09/28 10:45- Adicet Bio reported updated Phase 1 data for prula-cel in systemic lupus erythematosus, including patients with lupus nephritis.
- Results were released now, with an investor webcast scheduled for today.
- Patients showed sustained disease control with many reaching remission, alongside broad discontinuation of immunosuppressants and meaningful steroid tapering.
- Safety looked manageable, supporting outpatient use, with no severe cytokine release syndrome or serious neurologic immune-related events reported.
- Start-up activities for a single-arm pivotal lupus nephritis study are planned for 4Q/2026, with possible expansion into non-renal lupus.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
